NFE2L2 and Parkinson disease: In vivo evidence has demonstrated that dimethylfumarate (DMF), a pharmacological Nrf2 activator that has been shown to successfully reduce OS in multiple sclerosis (MS), may also have beneficial effects in PD [25,170,174].